These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7319736)

  • 41. Serum ostase in the follow-up of breast cancer patients.
    Marchei P; Santini D; Bianco V; Chiodini S; Reale MG; Simeoni F; Marchei GG; Vecchione A
    Anticancer Res; 1995; 15(5B):2217-22. PubMed ID: 8572628
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relation between urine zinc and hydroxyproline in rheumatoid arthritis and bone diseases.
    Ambanelli U; Ferraccioli GF; Bernardi P; Servemti G
    J Rheumatol; 1978; 5(4):477-9. PubMed ID: 739496
    [No Abstract]   [Full Text] [Related]  

  • 43. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases.
    Francini G; Gonnelli S; Petrioli R; Bruni S; Marsili S; Aquino A; Camporeale A
    Cancer Epidemiol Biomarkers Prev; 1993; 2(2):125-9. PubMed ID: 8467247
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of bilateral breast carcinoma: long-term results.
    Goksel HA; Yagmurdur MC; Karakayali H; Moray G; Demirhan B; Isiklar I; Bilgin N; Haberal M
    Int Surg; 2004; 89(3):166-71. PubMed ID: 15521255
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Collagen metabolism in patients with bone system tumors].
    Balaba TIa; Zatsepin ST; Furtseva LN
    Vopr Med Khim; 1971; 17(4):388-93. PubMed ID: 5317621
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Urinary hydroxyproline excretion in early and advanced breast cancer-a sequential study.
    Cuschieri A
    Br J Surg; 1973 Oct; 60(10):800-3. PubMed ID: 4748385
    [No Abstract]   [Full Text] [Related]  

  • 47. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients.
    Leeming DJ; Koizumi M; Byrjalsen I; Li B; Qvist P; Tankó LB
    Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):32-8. PubMed ID: 16434583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Three-centre study on urinary hydroxyproline excretion in cancer of the breast.
    Cuschieri A; Jarvie R; Taylor WH; Cant E; Furnival CM; Blumgart LH
    Br J Cancer; 1978 Jun; 37(6):1002-5. PubMed ID: 678421
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Total urinary hydroxyproline excretion before and after hypophysectomy in patients with bone metastases from breast carcinoma.
    Ditzel J; Jordal R; Riskaer N
    Acta Endocrinol (Copenh); 1968 Nov; 59(3):353-61. PubMed ID: 5754976
    [No Abstract]   [Full Text] [Related]  

  • 50. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Surgical treatment of bone metastases in patients with breast cancer.
    Dürr HR; Müller PE; Lenz T; Baur A; Jansson V; Refior HJ
    Clin Orthop Relat Res; 2002 Mar; (396):191-6. PubMed ID: 11859243
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hydroxyproline excretion in patients with breast cancer and response to treatment.
    Powles TJ; Leese CL; Bondy PK
    Br Med J; 1975 Apr; 2(5964):164-6. PubMed ID: 1125725
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Copper, zinc and superoxide dismutase in precancerous, benign diseases and gastric, colorectal and breast cancer.
    Magálová T; Bella V; Brtková A; Beno I; Kudlácková M; Volkovová K
    Neoplasma; 1999; 46(2):100-4. PubMed ID: 10466433
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Study of PBI 131 urinary elimination and collection located in breast carcinoma with or without metastasis].
    Richiger de Arranz E; Adrián R; Lencioni LJ; Staffieri JJ
    Medicina (B Aires); 1965; 25(6):345-7. PubMed ID: 15154228
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [A case of effective bisphosphonate therapy for bone metastasis from breast cancer with multiorganic metastases].
    Sueyoshi K; Ogura Y; Komori T; Takahashi M; Tian TX; Tatsumi T; Matsuki M; Saika Y; Uesugi Y; Utsunomiya K; Inomata Y; Narabayashi I
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1795-9. PubMed ID: 12402432
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Symptomatic relief for patients with osseous metastasis treated with radiation and methylprednisolone: a prospective randomized study.
    Teshima T; Inoue T; Inoue T; Ikeda H; Murayama S; Yamazaki H; Ohtani M; Kishi K; Miyata Y
    Radiat Med; 1996; 14(4):185-8. PubMed ID: 8916260
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Urinary tissue factor levels in patients with breast and colorectal cancer.
    Lwaleed BA; Chisholm M; Francis JL
    J Pathol; 1999 Feb; 187(3):291-4. PubMed ID: 10398081
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hydroxyproline excretion in the detection of occult bone metastases from breast cancer.
    Rowse AD; Morrison MJ; Scott PH; Banks AJ; Roginski C
    Oncology; 1982; 39(5):287-91. PubMed ID: 7099511
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Use of urinary hydroxyproline elimination in the detection of bone metastases secondary to prostatic carcinoma].
    de la Peña J; Cárcamo P; Martínez ME; Martínez-Piñeiro JA
    Actas Urol Esp; 1983; 7(3):199-204. PubMed ID: 6624563
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.